A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate

Overview

The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of methotrexate. Safety and tolerability of isavuconazole will be assessed alone and in combination with methotrexate.

Full Title of Study: “A Phase 1, Open- Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2013

Detailed Description

Subjects will check-in to the clinic on Day -1 and remain confined through completion of the study procedures on Day 10.

A follow-up telephone call will be made on Day 16 to check on health status.

Interventions

  • Drug: isavuconazole
    • oral
  • Drug: methotrexate
    • oral

Arms, Groups and Cohorts

  • Experimental: isavuconazole and methotrexate
    • Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 – 9

Clinical Trial Outcome Measures

Primary Measures

  • Pharmacokinetics (PK) of methotrexate in plasma: Area Under the Concentration-Time Curve (AUC) from the time of dosing to the last quantifiable concentration (AUClast)
    • Time Frame: Days 1 and 8 (15 plasma samples obtained from time zero to 36 hours post dose)
  • PK of methotrexate in plasma: AUC from the time of dosing to infinity (AUCinf)
    • Time Frame: Days 1 and 8 (15 plasma samples obtained from time zero to 36 hours post dose)
  • PK of methotrexate in plasma: Maximum Concentration (Cmax)
    • Time Frame: Days 1 and 8 (15 plasma samples obtained from time zero to 36 hours post dose)

Secondary Measures

  • PK variable for isavuconazole in plasma: Trough Concentration (Ctrough)
    • Time Frame: Days 6, 9 and 10 (1 sample prior to isavuconazole dosing)
  • Composite of PK variables for isavuconazole in plasma: AUCtau, Cmax and tmax
    • Time Frame: Days 7 and 8 (13 samples collected per day)
    • AUC during the time interval between consecutive dosing (AUCtau); the time after dosing when Cmax occurs (tmax)
  • Composite of PK variables for methotrexate in plasma: t1/2, tmax, CL/F and Vz/F
    • Time Frame: Days 1 and 8 (15 plasma samples obtained from time zero to 36 hours post dose)
    • Apparent Terminal Elimination Half-life (t1/2); Apparent Body Clearance After Oral Dosing (CL/F); Apparent Volume of Distribution (Vz/F)
  • Composite of PK variables for 7- hydroxymethotrexate in plasma: AUClast, AUCinf, t1/2, Cmax and tmax
    • Time Frame: Days 1 and 8 (15 plasma samples obtained from time zero to 36 hours post dose)

Participating in This Clinical Trial

Inclusion Criteria

  • The subject has a body weight of at least 45 kg and a body mass index of 18 to 32 kg/m2, inclusive.
  • QTcF must be 360 to 430 msec.
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and serum creatinine must not be above the normal range.
  • Male subject must be using highly effective contraception from Screening through 90 days after final study drug administration.
  • Male subject must not donate sperm starting at Screening through 90 days after final study drug administration.

Exclusion Criteria

  • The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of either Short or Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes).
  • The subject has a history of tuberculosis, or has a known or suspected immunodeficiency syndrome.
  • The subject has a positive result for hepatitis B surface antigen, hepatitis C antibodies or QuantiFERON®-TB Gold test(s) at Screening or is known to be positive for human immunodeficiency virus.
  • The subject has a known or suspected allergy to any of the components of the trial products or the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods, or a history of severe anaphylactic reactions.
  • The subject is a smoker (any use of tobacco or nicotine containing products) in the last 6 months.
  • The subject has had treatment with any prescribed or non-prescribed drugs in the 2 weeks prior to Day 1, with the exception of occasional use of acetaminophen up to 2 g/day.
  • The subject has participated in any interventional clinical study or has received any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to Screening.
  • The subject has participated in a prior study with isavuconazole.
  • The subject has history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening or the subject tests positive at screening or Day -1 for alcohol or drugs of abuse.
  • The subject is an employee of the Astellas Group or vendors involved in the study.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Astellas Pharma Global Development, Inc.
  • Collaborator
    • Basilea Pharmaceutica International Ltd
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Medical Director, Study Director, Astellas Pharma Global Development, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.